| Literature DB >> 35449994 |
Dania AlKhafaji1, Reem Al Argan1, Salma Albahrani2, Abdulmohsen Al Elq1, Waleed Albaker1, Mohammed Al-Hariri3, Abrar Alwaheed1, Safi Alqatari1, Alaa Alzaki1, Abir Alsaid1, Marwan Alwazzeh1, Fatimah AlRubaish1, Zainab Alelq1, Tariq Alsaif1, Mohammad Zeeshan4, Nada Alzahrani2, Abdulrahman Alhusil2, Batool Gasmelseed2, Fatma Zainuddin5, Amani Alhwiesh1, Nafie Alrubaish1.
Abstract
This study aimed to assess the association of obesity with the severity and outcome of COVID-19 infection. A retrospective observational study was performed from March to September 2020 in Saudi Arabia. Baseline and laboratory data were collected from the inpatient health record system. The cohort was divided into three groups based on body mass index. Following this, the severity and outcome of COVID-19 disease were analyzed between the three groups. Of the 502 COVID-19 cases included, 244 (48.5%) were obese. Obesity was significantly associated with severe (53.5%) or critical (28%) COVID-19 infection (P<0.001) and a higher need for ICU admission (35.8%, P=0.034). Multivariate analysis showed that overweight/obesity was an independent risk factor of severe (P<0.001) as well as critical COVID-19 infection (P=0.026, respectively) and a predictor of a higher risk of ICU admission (P=0.012). Class I obesity was associated with severe-critical COVID-19 disease (33.6%, P=0.042) compared to other obesity classes. Obesity is an independent risk factor for severe-critical COVID-19 infection and a higher risk of ICU admission. Clinicians should give special attention to such populations and prioritize vaccination programs to improve outcomes. ©Carol Davila University Press.Entities:
Keywords: COVID-19; body mass index; mortality; obesity; outcome; severity
Mesh:
Year: 2022 PMID: 35449994 PMCID: PMC9015180 DOI: 10.25122/jml-2022-0033
Source DB: PubMed Journal: J Med Life ISSN: 1844-122X
Demographic data of participants.
| Frequency | Percentage | ||
|---|---|---|---|
|
|
| 326 | 64.9 |
|
| 176 | 35.1 | |
|
|
| 369 | 73.5 |
|
| 133 | 26.5 | |
|
|
| 9 | 1.8 |
|
| 111 | 22.1 | |
|
| 217 | 43.2 | |
|
| 151 | 30.1 | |
|
| 14 | 2.8 | |
|
|
| 109 | 21.8 |
|
| 149 | 29.7 | |
|
| 244 | 48.6 | |
|
|
| 135 | 55.3 |
|
| 58 | 23.8 | |
|
| 51 | 20.9 | |
|
|
| 148 | 29.5 |
|
| 202 | 40.2 | |
|
| 152 | 30.3 | |
|
|
| 200 | 39.92 |
|
| 195 | 38.92 | |
|
| 94 | 18.76 | |
|
| 122 | 24.35 | |
DM – diabetes mellitus; HTN – hypertension; BMI – body mass index; CKD – chronic kidney disease.
Laboratory findings among COVID-19 groups according to BMI.
| Laboratory parameter | Normal range | Median (IQR) | P-values | ||
|---|---|---|---|---|---|
| Normal weight | Overweight | Obese | |||
|
| (4.0–10.0 k/ul) | 7.3 (3.8–11.6) | 8.9 (4.4–14.9) | 9.8 (5.4–14.7) | 0.052 |
|
| Females (12.0–16.0 g/dl) | 12.8 (11.9–14) | 13 (12.7–14.7) | 13.7 (11.9–14.4) | 0.244 |
| Males (13.0–18.0 g/dl) | |||||
|
| (140–450) | 196.5 (149.5–252) | 190 (158–247) | 212 (155–260) | 0.858 |
|
| (2.0–7.5 k/uL) | 4.6 (2.4–8.3) | 7 (3–10.9) | 7.1 (3.4–11.8) | 0.053 |
|
| (1.0–5.0 k/ul) | 1.1 (0.8–2) | 1 (0.7–1.3) | 1.3 (0.9–1.7) |
|
|
| (7–26 mg/dl) | 12.6 (9–18.9) | 13.7 (10–19) | 15 (11–23) |
|
|
| (0.6–1.2 mg/dl) | 0.9 (0.7–1.2) | 1 (0.8–1.2) | 1 (0.8–1.3) | 0.066 |
|
| (136–146 mEq/L) | 135 (131–137.5) | 135 (133–139) | 136 (132–137) | 0.271 |
|
| (3.5–5.1 mEq/L) | 4 (3.8–4.5) | 4.2 (3.6–4.5) | 4.2 (3.8–4.5) | 0.062 |
|
| (20–31 mEq/L) | 23 (21–26) | 23 (21–26) | 24 (20–26) | 0.766 |
|
| (81–234 U/L | 376 (297.5–515) | 376 (281–608) | 411 (304–570) | 0.557 |
|
| (0–20 mm/hour) | 48.5 (26.5–75) | 52 (39–72) | 52 (32–67) | 0.811 |
|
| (0.1-0.5 mg/dl) | 8.3 (3.6–17.7) | 8.9 (4.1–18.8) | 10.2 (5.2–18.4) | 0.535 |
|
| ≤0.5 ug/mL | 1 (0.5–3.4) | 0.8 (0.5–1.4) | 1.1 (0.6–1.7) | 0.986 |
|
| (21.81–274.66 ng/ml) | 325 (131–741) | 548 (214–1311.1) | 591 (270–1154) |
|
WBCs – white blood cells; Hgb – Hemoglobin; Na – Sodium; K – Potassium; Cl – chloride; CO2 – Carbon dioxide; LDH – Lactate dehydrogenase; ESR – Erythrocyte sedimentation rate; CRP – C-reactive protein; bold – Significant value.
Association between severity of COVID-19 infection with co-morbidities, age, and gender.
| Variable | Severity | P-value | |||
|---|---|---|---|---|---|
| Mild-Moderate | Severe | Critical | |||
|
|
| 93 (28.5%) | 129 (39.6%) | 104 (31.9%) | 0.53 |
|
| 55 (30.7%) | 73 (40.8%) | 48 (26.8%) | ||
|
|
| 3 (33.3%) | 5 (55.6%) | 1 (11.1%) | 0.21 |
|
| 36 (32.4%) | 51 (45.9%) | 24 (21.6%) | ||
|
| 57 (26.3%) | 90 (41.5%) | 70 (32.3%) | ||
|
| 46 (30.5%) | 50 (33.1%) | 55 (36.4%) | ||
|
| 6 (42.9%) | 6 (42.9%) | 2 (14.3%) | ||
|
|
| 54 (27%) | 92 (46%) | 54 (27%) | 0.3 |
|
| 51 (26.2%) | 82 (42.1%) | 62 (31.8%) | 0.5 | |
|
| 27 (28.7%) | 28 (29.8%) | 39 (41.5%) |
| |
|
| 31 (25.4%) | 47 (38.5%) | 44 (36.1%) | 0.3 | |
Univariate analysis test. Bold – Significant value.
Association between outcomes and severity of COVID-19 infection according to BMI.
|
|
|
| |||
|
|
|
| |||
|
|
| 45 (41.3%) | 57 (38.3%) | 46 (18.8%) |
|
|
| 29 (26.6%) | 43 (28.9%) | 130 (53.3%) | ||
|
| 35 (32.1%) | 49 (32.9%) | 68 (27.9%) | ||
|
|
| ||||
|
| 56 (51.4%) | 64 (42.9%) | 28 (11.5%) |
| |
|
| |||||
|
| 13 (11.9%) | 20 (13.4%) | 133 (54.7%) |
| |
|
| 17 (15.6%) | 35 (23.5%) | 119 (49%) |
| |
|
| 7 (6.4%) | 20 (13.4%) | 57 (23.5%) |
| |
|
| 8 (7.3%) | 13 (8.7%) | 127 (52.3%) |
| |
|
| |||||
|
| 16 (14.7%) | 24 (16.1%) | 45 (18.5%) | 0.64 | |
|
| 11 (10.1%) | 16 (10.7%) | 37 (15.2%) | 0.277 | |
|
| 11 (10.1%) | 16 (10.7%) | 21 (8.6%) | 0.778 | |
|
| 5 (4.6%) | 8 (5.4%) | 18 (7.4%) | 0.528 | |
|
| 12 (16.5%) | 23 (15.4%) | 15 (6.2%) |
| |
|
| 17 (15.6%) | 12 (8.1%) | 23 (9.5%) | 0.118 | |
|
|
| 7 (3–11) | 8 (4–14) | 7 (4–12) | 0.35 |
|
| 24 (22) | 50 (33.6) | 87 (35.8%) |
| |
|
| 15 (13.8%) | 26 (17.4%) | 43 (17.7%) | 0.7 | |
|
| 9 (8.3%) | 11 (7.4%) | 22 (9.1%) | 0.8 | |
Univariate analysis test. BMI – Body mass index; PaO2 – Partial pressure of oxygen; FiO2 – Fraction of inspired oxygen; LDH – lactate dehydrogenase; IQR – Interquartile range; ICU – Intensive care unit; N – number; % – percentage; bold – Significant value.
Figure 1.Association between outcomes and severity of COVID-19 infection with the three study groups. Univariate analysis test. ICU – Intensive care unit.
Association between outcomes and severity of COVID-19 infection with BMI, co-morbidities, age, and gender.
| Variable | Severity | Outcome | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Severe | Critical | *Hospital stay | ICU admission | Mechanical ventilation | Death | |||||||
| OR | P-value | OR | P-values | OR | P-values | OR | P-values | OR | P-values | OR | P-value | |
|
| 0.8 (0.5–1.1) | 0.12 | 1.03 (0.7–1.5) | 0.8 | 1.72 (1.3–2.27) |
| 2.07 (0.4–10.7) |
| 1.63 (0.8–2.9) |
| 2.15 (0.5–11) |
|
|
| 1.1 (0.7–1.6) | 0.8 | 1.3 (0.8–2.1) | 0.2 | 2.11 (1.37–3.25) |
| 2.12 (0.5–11.7) |
| 1.530 (0.9–2.6) | 0.159 | 1.236 (0.7–2.2) | 0.576 |
|
| 1.4 (0.8–2.3) | 0.22 | 0.6 (0.3–1.1) | 0.9 | 1.31 (0.84–2.04) | 0.235 | 1.184 (0.5–2.6) | 0.482 | 1.239 (0.7–2.2) | 0.476 | 1.254 (0.7–2.2) | 0.551 |
|
| 1.3 (0.7–2.2) | 0.4 | 1.01 (0.6–1.7) | 0.6 | 0.85 (0.53–1.37) | 0.514 | 0.59 (0.4–1.6) |
| 0.48 (0–3.1) |
| 0.32 (0.1–4.1) |
|
|
| 0.6 (0.3–1.3) | 0.2 | 1.2 (0.6–2.3) | 0.5 | 0.63 (0.35–1.12) | 0.118 | 1.287 (0.7–2.2) | 0.410 | 0.540 (0.4–1.6) | 0.062 | 0.620 (0.5–2.6) | 0.233 |
|
| 1.3 (0.7–2.3) | 0.4 | 1.9 (1.1–3.5) |
| 2 (1.25–3.2) |
| 1.079 (0.4–2.8) | 0.764 | 0.737 (0.4–2.6) | 0.304 | 1.338 (0.8–3.2) | 0.468 |
|
| 2.4 (1.8–3.2) |
| 1.4 (1–2) |
| 1.01 (0.98–1.04) | 0.582 | 1 (0.2–2.4) |
| 1.009 (0.2–1.4) | 0.647 | 1.010 (0.1–1.9) | 0.709 |
Multivariate analysis test. OR–Odds ratio; CI–Confidence Interval; DM–Diabetes mellitus; HTN–hypertension; BMI–Body mass index; CKD–chronic kidney disease. *Hospital stay: we used a cutoff of 7 days correlated with the mean hospital stay of COVID-19 disease patients in previous studies [43]. Significant values are shown in bold.
The effect of gender, age, and obesity classes on the outcomes and severity of COVID-19 infection.
| Variable | Severe-Critical | *Hospital Stay | ICU Admission | Mechanical ventilation | Death |
|---|---|---|---|---|---|
|
| |||||
| ≤40 years (n=56) | 48 (85.7%) | 19 (35.2%) | 12 (21.4%) | 5 (8.9%) | 1 (1.8%) |
| >40 years (n=188) | 150 (79.8%) | 96 (51.1%) | 75 (39.9%) | 38 (20.2%) | 21 (11.2%) |
| P-Value | 0.35 |
|
| 0.050 |
|
|
| |||||
| Male (n=146) | 118 (80.8%) | 77 (52.7%) | 56 (38.4%) | 27 (18.5%) | 13 (8.9%) |
| Female (n=98) | 80 (81.6%) | 38 (39.2%) | 31 (31.6%) | 16 (16.3%) | 9 (9.2%) |
| P-Value | 0.96 |
| 0.265 | 0.63 | 0.713 |
|
| |||||
| Class1 | 45 (33.3%) | 62 (45.9%) | 49 (35.6%) | 25 (18.5%) | 12 (8.9%) |
| Class 2 | 11 (19%) | 29 (50%) | 21 (36.2%) | 13 (22.4%) | 8 (13.8%) |
| Class 3 | 12 (23.5%) | 24 (47.1%) | 17 (33.3%) | 5 (9.8%) | 2 (3.9%) |
| P-Value |
| 0.865 | 0.9 | 0.207 | 0.202 |
*Hospital stay: we used a cutoff of 7 days correlated with the mean hospital stay of COVID-19 disease patients in previous studies [43]. Bold – Significant value.